Omega-3 and hemocompatibility-related adverse events.

ABSTRACT:

Background

Hemocompatibility-related clinical adverse events (HRAEs) are major causes of readmission in patients with left ventricular assist devices (LVADs). Omega-3 is an unsaturated fatty acid that possesses anti-inflammatory and antiangiogenic properties. We aimed to investigate the impact of omega-3 therapy on HRAEs during LVAD support.

Methods

Consecutive LVAD patients who were followed for 6 months were enrolled, and stratified by the use of omega-3. Freedom from any HRAEs and net burden of HRAEs, which was calculated by using a hemocompatibility score (using 4 escalating tiers of hierarchal severity to derive a total score for events), were compared between those with and without omega-3 therapy.

Results

Among 169 LVAD patients (57 years old and 124 males), 31

SUBMITTER: Imamura T 

PROVIDER: S-EPMC7135915 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature